TransMedics Capital Surpluse from 2010 to 2025

TMDX Stock  USD 57.20  0.82  1.41%   
TransMedics Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 158.1 M in 2025. During the period from 2010 to 2025, TransMedics Capital Surpluse regression line of annual values had r-squared of  0.32 and arithmetic mean of  145,939,250. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
165.4 M
Current Value
158.1 M
Quarterly Volatility
6.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 13 M, Selling General Administrative of 144.4 M or Research Development of 76.4 M, as well as many indicators such as Price To Sales Ratio of 11.6, Dividend Yield of 0.0 or PTB Ratio of 17.68. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
  
Check out the analysis of TransMedics Correlation against competitors.

Latest TransMedics' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of TransMedics Group over the last few years. It is TransMedics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

TransMedics Capital Surpluse Regression Statistics

Arithmetic Mean145,939,250
Geometric Mean145,819,757
Coefficient Of Variation4.32
Mean Deviation3,944,188
Median143,794,000
Standard Deviation6,301,609
Sample Variance39.7T
Range21.8M
R-Value0.56
Mean Square Error29.1T
R-Squared0.32
Significance0.02
Slope745,120
Total Sum of Squares595.7T

TransMedics Capital Surpluse History

2025158.1 M
2024165.4 M
2018143.8 M

About TransMedics Financial Statements

TransMedics investors use historical fundamental indicators, such as TransMedics' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse165.4 M158.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.